Compounded vs Brand GLP-1 Safety: What Patients Need to Know in 2025

Why This Comparison Matters Right Now

The FDA shortage designations for both semaglutide and tirzepatide have ended, which changed the legal rules for compounding more than most patients realize. Semaglutide was removed from the FDA drug shortage database in February 2025, and tirzepatide in October 2024 [1]. Those two dates matter because federal law under 21 U.S.C. § 503B ties the right of outsourcing facilities to produce large compounded batches directly to active shortage status. Once the shortage resolves, 503B mass production of a copy of an approved drug becomes legally prohibited.

The practical effect for patients: if you received compounded semaglutide from a 503B facility after February 2025, or compounded tirzepatide from a 503B facility after October 2024, that product was likely produced outside the legal compounding window. That does not automatically mean it is unsafe, but it does mean it bypassed the oversight structure designed to catch sterility failures, incorrect potency, and unlabeled excipients.

Brand-name products are manufactured in FDA-inspected facilities under current Good Manufacturing Practice (cGMP) regulations. Every lot is tested for identity, potency, sterility, and stability before release [2]. Compounded drugs, even those from well-run pharmacies, do not go through that same pre-release review.

How the Brand GLP-1 Drugs Performed in Clinical Trials

Brand efficacy data is the baseline against which any compounded product should be measured, because no compounded GLP-1 has its own randomized controlled trial data.

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean 14.9% body weight reduction at 68 weeks compared with 2.4% for placebo (P<0.001) [3]. The trial enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. STEP-3 (N=611) confirmed that adding intensive behavioral therapy to semaglutide 2.4 mg raised mean weight loss to 16.0% at 68 weeks [4].

For tirzepatide, SURMOUNT-1 (N=2,539) showed mean weight reductions of 15.0%, 19.5%, and 20.9% at doses of 5 mg, 10 mg, and 15 mg respectively at 72 weeks, with the highest-dose arm reaching 22.5% in participants without diabetes (P<0.001 vs placebo) [5]. SURMOUNT-4 (N=670) later demonstrated that withdrawing tirzepatide after 36 weeks of treatment led to 14% weight regain by week 88, while continuing the drug maintained a 5.5% additional reduction [6]. Stopping treatment, regardless of whether the product is brand or compounded, carries a real biological cost.

The cardiovascular evidence is strongest for brand semaglutide. The SELECT trial (N=17,604) found that semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 33.3 months [7]. No compounded formulation has this evidence base.

The 503A vs 503B Distinction: A Safety-Critical Difference

These two regulatory categories are not interchangeable, and the difference between them affects every safety question a patient should ask.

503A pharmacies compound medications for specific, identified patients under a valid prescription from a licensed practitioner [8]. They operate under state board of pharmacy oversight. Each preparation is made to order. They are not subject to FDA pre-approval of their processes, but they are also not permitted to produce large anticipatory batches for general sale. A well-run 503A pharmacy that sources pharmaceutical-grade API (active pharmaceutical ingredient), maintains documented sterility records, and dispenses under a real prescriber relationship represents the safer end of the compounding spectrum.

503B outsourcing facilities are federally registered, subject to FDA inspection, and can produce larger sterile batches without patient-specific prescriptions [9]. During the GLP-1 shortage period (roughly 2022 to early 2025), 503B facilities were the legal backbone of compounded GLP-1 supply. That pathway is now closed for semaglutide and tirzepatide because the shortage designations have ended.

The safety gap between these two categories shows up in adverse event reports. The FDA received numerous MedWatch reports between 2023 and 2025 involving compounded semaglutide products with dosing errors, particulate matter, and contamination. In many cases the source was either an unregistered compounder or a 503A pharmacy that had exceeded its legal scope by producing bulk batches [10].

Salt Forms: The Specific Risk Most Patients Miss

Pharmaceutical-grade semaglutide, as used in Ozempic and Wegovy, is semaglutide free base. Some compounding pharmacies have used semaglutide sodium or semaglutide acetate because these salt forms were more readily available from API suppliers during the shortage.

The FDA issued warning letters in 2024 citing this practice explicitly. The agency stated that salt forms of semaglutide are not the same active ingredient as the approved drug, meaning a product compounded from semaglutide sodium is not a permissible copy of Wegovy or Ozempic under the compounding exemption [10]. Potency, bioavailability, and injection-site tolerability may all differ. Patients should ask their pharmacy in writing which specific molecular form of the API they are using and request a certificate of analysis from an accredited third-party lab.

The HealthRX pharmacy verification framework below summarizes what to ask before filling any compounded GLP-1 prescription.

HealthRX Compounded GLP-1 Pharmacy Verification Checklist:

1. Is the pharmacy registered as a 503A or 503B facility? (Ask for their DEA registration number and state board license number.)
2. Does the pharmacy source API from an FDA-registered supplier? (Request the supplier's name and their FDA registration number.)
3. What molecular form of semaglutide or tirzepatide is used? (Free base is required to match the approved drug standard.)
4. Can the pharmacy provide a certificate of analysis from an independent, ISO-accredited lab for your specific lot?
5. Is the prescriber associated with the pharmacy licensed in your state and conducting a real clinical evaluation?
6. Is the pharmacy listed in the NABP (National Association of Boards of Pharmacy) Verified Pharmacy Program or a state board database?

A pharmacy that cannot answer questions 1 through 4 in writing should not be filling GLP-1 prescriptions.

Legal Status of Compounded GLP-1s After the Shortage Ended

Patients sometimes read that compounded GLP-1s are now "illegal." That framing is too broad. What changed is the scope of who can legally compound these drugs and under what conditions.

503B mass compounding of semaglutide or tirzepatide copies is prohibited now that both shortages have resolved [1]. 503A patient-specific compounding remains legal when a licensed prescriber issues a valid, individualized prescription for a specific patient with a documented clinical need [8]. Some clinical situations still support 503A compounding, including patients who need a dose strength not available commercially, patients with confirmed allergies to an excipient in the brand product, or patients in documented financial hardship for whom the brand product is inaccessible.

The FDA has also clarified that certain "office use" compounding by 503A pharmacies, where batches are sent to clinics without a patient-specific order, does not qualify for the compounding exemption. Telehealth platforms that auto-ship compounded GLP-1 vials before a clinical evaluation is complete almost certainly operate in this gray area.

Two direct quotations from FDA guidance are worth putting on record here. The FDA's 2024 compliance policy guidance stated: "A drug product that is essentially a copy of a commercially available drug product that is not on the shortage list may not be compounded under section 503B." [11] And from the agency's 503A guidance: "Compounded drugs are not FDA-approved. This means FDA has not verified the safety, effectiveness, or quality of compounded drugs." [8]

What Brand Products Actually Guarantee

The FDA approval process for Wegovy and Zepbound required multi-year clinical programs, manufacturing site inspections, and post-market surveillance commitments. The Wegovy label specifies the exact injection device, diluent, storage temperature range (36 to 46 degrees Fahrenheit), and the dose-escalation schedule to reduce gastrointestinal side effects [12]. The Zepbound label similarly defines the 2.5 mg starting dose and the four-week titration intervals [13].

Patients using brand products receive a pen injector with a fixed dose per click, a label that has been reviewed for accuracy, and a lot-traceable product that can be recalled if a manufacturing problem is identified. Compounded vials require the patient to draw up their own dose with a syringe. Dosing errors in that step are a real and documented source of adverse events.

The STEP-5 trial (N=304) followed patients on semaglutide 2.4 mg for 104 weeks and found sustained mean weight loss of 15.2% with a well-characterized side-effect profile that did not worsen over time [14]. That kind of long-term safety signal exists only for the brand-formulated molecule.

Cost, Access, and When Compounded May Still Be Appropriate

Brand GLP-1 medications carry list prices between $900 and $1,400 per month in the United States without insurance coverage. Compounded versions have ranged from $150 to $500 per month from legitimate pharmacies. That cost gap is real, and it affects patient adherence.

The AACE/ACE obesity clinical practice guidelines recognize that access barriers, including cost, are legitimate clinical considerations in selecting a treatment approach [15]. A patient who cannot afford Wegovy and discontinues treatment entirely faces worse outcomes than a patient on a properly compounded product from an accredited 503A pharmacy.

The safety calculus changes, though, when a compounded product comes from an unverified source. The FDA identified more than 20 compounding pharmacies between 2023 and 2025 that were producing GLP-1 medications without adequate sterility controls, using unapproved salt forms, or shipping products with incorrect concentration labels [10]. Adverse event reports included hospitalizations for hypoglycemia from dosing errors and infections at injection sites from non-sterile preparations.

Patients who genuinely cannot access brand products should work with a physician to identify a NABP-accredited 503A pharmacy, confirm API source and molecular form, and receive a certificate of analysis before starting. Patients who can access Wegovy or Zepbound through insurance, manufacturer savings programs (both Novo Nordisk and Eli Lilly offer patient assistance), or employer benefits should use the brand product.

How to Verify Your Pharmacy Before You Order

The NABP maintains a searchable database of accredited pharmacies at nabp.pharmacy. State boards of pharmacy also maintain public license lookup tools. For any compounding pharmacy, you should be able to confirm:

The pharmacy holds a valid state license in the state where it operates and in your state if it ships across state lines. The pharmacy is either registered as a 503B outsourcing facility with the FDA (searchable at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities) or holds a current 503A pharmacy license with documented sterility testing protocols. The prescriber is independently licensed, not employed exclusively by the pharmacy, and conducted a real evaluation before issuing the prescription.

Telehealth platforms that advertise compounded GLP-1s without requiring lab work, medical history, or a synchronous or asynchronous clinical consultation should raise concern. Legitimate prescribing follows the standard of care described in AACE/ACE guidelines, which includes BMI assessment, comorbidity screening, and monitoring for contraindications including personal or family history of medullary thyroid carcinoma [15].

Side Effect Profiles: Brand vs Compounded

The known side effect profile of semaglutide includes nausea (44% of participants in STEP-1 vs 16% placebo), vomiting, diarrhea, and constipation, with most gastrointestinal events occurring during dose escalation [3]. Tirzepatide in SURMOUNT-1 showed nausea in 31% of the 15 mg group vs 9% placebo [5]. These rates were established with the exact formulation, excipients, and delivery device used in the approved product.

Compounded formulations may use different buffers, preservatives, or pH adjusters. Those changes can affect injection-site tolerability, absorption rate, and gastrointestinal side effect frequency. No head-to-head safety trial has compared a compounded GLP-1 to the brand product in a controlled setting. That evidence gap is not a theoretical concern; it is the defining limitation of compounded medications across all drug classes.

Patients should also know that the known risk of thyroid C-cell tumors seen in rodent studies led the FDA to require a boxed warning on both Wegovy and Zepbound labels [12][13]. That warning applies to the active molecule regardless of whether it comes from a brand pen or a compounded vial. The contraindication for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 applies equally to both product types.

STEP and SURMOUNT Data Do Not Transfer to Compounded Products

A point worth stating plainly: when a clinician cites STEP-1 or SURMOUNT-1 to explain what a patient can expect from their GLP-1 therapy, those projections assume the patient is receiving the molecule in the exact form, dose, and delivery system studied in those trials.

SURMOUNT-2 (N=938) studied tirzepatide specifically in patients with type 2 diabetes and found mean A1C reductions of 2.01% (15 mg) vs 0.03% placebo at 72 weeks (P<0.001) [16]. STEP-2 (N=1,210) found semaglutide 2.4 mg reduced A1C by 1.6 percentage points vs 0.4% for placebo in patients with type 2 diabetes [17]. These metabolic benefits depend on consistent, accurate dosing of the correct molecular form. Variability in compounded products, whether from potency drift, incorrect concentration, or salt-form substitution, could attenuate these outcomes in ways that are difficult to detect without regular lab monitoring.

Patients on compounded GLP-1 therapy should have fasting glucose, A1C (if diabetic or prediabetic), and weight measured at minimum every 12 weeks to confirm the expected treatment response is occurring.